Lv0
0 积分 2022-07-06 加入
Response to Crizotinib After Entrectinib Resistance in ROS1 -Rearranged, MET -Amplified Lung Adenocarcinoma
2小时前
已完结
Ovarian Cancer：A Review
2个月前
已完结
Prognostic significance of Dickkopf-1 in head and neck squamous cell carcinoma
6个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
7个月前
已完结
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
7个月前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
9个月前
已完结
皖公网安备34019202002308
